نتائج البحث

المساهمون: Nowakowski G.S., Yoon D.H., Mondello P., Joffe E., Peters A., Fleury I., Greil R., Ku M., Marks R., Kim K., Zinzani P.L., Trotman J., Sabatelli L., Waltl E.E., Winderlich M., Sporchia A., Kurukulasuriya N.C., Cordoba R., Hess G., Salles G.

مصطلحات موضوعية: DLBCL, Lenalidomide, Real-world, Relapsed/Refractory, Tafasitamab

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37171597; info:eu-repo/semantics/altIdentifier/wos/WOS:000988206000004; volume:102; issue:7; firstpage:1773; lastpage:1787; numberofpages:15; journal:ANNALS OF HEMATOLOGY; https://hdl.handle.net/11585/960119Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85159261558; https://link.springer.com/article/10.1007/s00277-023-05196-4Test

الإتاحة: https://doi.org/10.1007/s00277-023-05196-4Test
https://hdl.handle.net/11585/960119Test

View record in BASE

5

دورية أكاديمية

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study

المؤلفون: Shadman, M, Manzoor, BS, Sail, K, Tuncer, HH, Allan, JN, Ujjani, C, Emechebe, N, Kamalakar, R, Coombs, CC, Leslie, L, Barr, PM, Brown, JR, Eyre, TA, Rampotas, A, Schuh, A, Lamanna, N, Skarbnik, A, Roeker, LE, Bannerji, R, Eichhorst, B, Fleury, I, Davids, MS, Alhasani, H, Jiang, D, Hill, BT, Schuster, SJ, Brander, DM, Pivneva, I, Burne, R, Guerin, A, Mato, AR

المصدر: Clinical Lymphoma, Myeloma & Leukemia (2023) (In press).

مصطلحات موضوعية: Adverse events, Chemoimmunotherapy, Chemotherapy, Disease progression, Targeted agents

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10171712/1/Treatment%20Discontinuation%20CLL.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10171712Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10171712/1/Treatment%20Discontinuation%20CLL.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10171712Test/

View record in BASE

6

دورية أكاديمية

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

المؤلفون: Schuster, SJ, Tam, CS, Borchmann, P, Worel, N, McGuirk, JP, Holte, H, Waller, EK, Jaglowski, S, Bishop, MR, Damon, LE, Foley, SR, Westin, JR, Fleury, I, Ho, PJ, Mielke, S, Teshima, T, Janakiram, M, Hsu, JM, Izutsu, K, Kersten, MJ, Ghosh, M, Wagner-Johnston, N, Kato, K, Corradini, P, Martinez-Prieto, M, Han, X, Tiwari, R, Salles, G, Maziarz, RT

المصدر: The Lancet. Oncology. 22(10):1403-1415

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:147888104Test

7

دورية أكاديمية

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

المؤلفون: Nowakowski G. S., Yoon D. H., Peters A., Mondello P., Joffe E., Fleury I., Greil R., Ku M., Marks R., Kim K., Zinzani P. L., Trotman J., Huang D., Waltl E. E., Winderlich M., Kurukulasuriya N. C., Ambarkhane S., Hess G., Salles G.

المساهمون: Nowakowski G.S., Yoon D.H., Peters A., Mondello P., Joffe E., Fleury I., Greil R., Ku M., Marks R., Kim K., Zinzani P.L., Trotman J., Huang D., Waltl E.E., Winderlich M., Kurukulasuriya N.C., Ambarkhane S., Hess G., Salles G.

مصطلحات موضوعية: Tafasitamab plus Lenalidomide, Systemic Therapies, Relapsed/Refractory DLBCL: RE-MIND2

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35674661; info:eu-repo/semantics/altIdentifier/wos/WOS:000856065600001; volume:28; issue:18; firstpage:4003; lastpage:4017; numberofpages:15; journal:CLINICAL CANCER RESEARCH; https://hdl.handle.net/11585/904775Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85138444892; https://aacrjournals.org/clincancerres/article/28/18/4003/708997/Improved-Efficacy-of-Tafasitamab-plus-LenalidomideTest

الإتاحة: https://doi.org/10.1158/1078-0432.CCR-21-3648Test
https://hdl.handle.net/11585/904775Test
https://aacrjournals.org/clincancerres/article/28/18/4003/708997/Improved-Efficacy-of-Tafasitamab-plus-LenalidomideTest

View record in BASE

8

دورية أكاديمية

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

المؤلفون: Nowakowski, GS, Yoon, DH, Peters, A, Mondello, P, Joffe, E, Fleury, I, Greil, R, Ku, M, Marks, R, Kim, K, Zinzani, PL, Trotman, J, Huang, D, Waltl, EE, Winderlich, M, Kurukulasuriya, NC, Ambarkhane, S, Hess, G, Salles, G

العلاقة: pii: 704803; Nowakowski, G. S., Yoon, D. H., Peters, A., Mondello, P., Joffe, E., Fleury, I., Greil, R., Ku, M., Marks, R., Kim, K., Zinzani, P. L., Trotman, J., Huang, D., Waltl, E. E., Winderlich, M., Kurukulasuriya, N. C., Ambarkhane, S., Hess, G. & Salles, G. (2022). Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. CLINICAL CANCER RESEARCH, 28 (18), pp.4003-4017. https://doi.org/10.1158/1078-0432.CCR-21-3648Test.; http://hdl.handle.net/11343/318231Test

الإتاحة: https://doi.org/10.1158/1078-0432.CCR-21-3648Test
http://hdl.handle.net/11343/318231Test

View record in BASE

النص الكامل